2024
Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study
Petrakis I, Nolen T, Vandergrift N, Hirsch S, Krystal J, De Vivo M, Sabados J, Pisani E, Newcomb J, Kosten T. Dexmedetomidine HCL (BXCL501) as a potential treatment for alcohol use disorder and comorbid PTSD: A phase 1b, placebo‐controlled crossover laboratory study. American Journal On Addictions 2024 PMID: 39152094, DOI: 10.1111/ajad.13637.Peer-Reviewed Original ResearchPathophysiology of posttraumatic stress disorderAlcohol use disorderSubjective effects of alcoholEffects of alcoholUse disorderComorbid alcohol use disorderAlcohol cue reactivityPosttraumatic stress disorderCrossover laboratory studyCue reactivityAlcohol cravingNoradrenergic dysregulationStress disorderBlood pressureSubjective effectsEthanol administrationClinically significant adverse effectsPharmacotherapeutic approachesTest daysReceptor agonistsPotential treatmentDouble-blind fashionCravingDrinking alcoholDisorders
1997
Benzodiazepine Receptor Antagonists
Abi-Dargham A, Charney D, Krystal J. Benzodiazepine Receptor Antagonists. CNS Drugs 1997, 8: 244-256. DOI: 10.2165/00023210-199708030-00007.Peer-Reviewed Original ResearchBenzodiazepine receptorsIdiopathic recurrent stuporBenzodiazepine receptor antagonistPotential therapeutic benefitBenzodiazepine toleranceCerebral ischaemiaGABAergic systemΓ-aminobutyric acidReceptor antagonistMovement disordersNeuronal markersSleep disordersTherapeutic benefitCognitive disordersPotential treatmentNeuropsychiatric illnessOnly agentInverse agonistFlumazenilPharmacological investigationsAdverse effectsReceptorsDisordersImaging agentEpilepsy